Meeting abstracts The PD-1/PD-L1 blockade is now recognized as one of the basic immune interventions for development of combination cancer immunotherapy. We have been screening chemical libraries to obtain compounds which have an activity to augment anti-tumor activity of the PD-1/PD-L1 blockade.
No takes yet. Share an insight, caveat, or question.
Hayakawa et al. (2014) studied this question.